

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**COMMON SPLENDOR INTERNATIONAL
HEALTH INDUSTRY GROUP LIMITED**

(Incorporated in Bermuda with limited liability)
(Stock Code: 286)

CLARIFICATION ANNOUNCEMENT

AND

DISCLOSEABLE TRANSACTION

Reference is made to the announcement dated 21 July 2014 of Common Splendor International Health Industry Group Limited (the "Announcement"). Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement unless the context otherwise requires.

The Board would like to clarify that since one of the percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the transactions contemplated under the Joint Venture Agreement exceeds 5% but less than 25%, the transactions contemplated thereunder constitute a discloseable transaction of the Company and is subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules, instead of "none of the percentage ratios calculated pursuant to Rule 14.07 of the Listing Rules in respect of the transactions contemplated under the Joint Venture Agreement exceed 5%, the transactions contemplated thereunder do not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules" which was stated in paragraph 2 under the section "Listing Rules Implication" on page 3 of the Announcement.

The Company further clarified the following matters:

The proposed registered capital of the Joint Venture Company will be RMB30 million. The proposed registered capital of Joint Venture Company shall be contributed by CS Fund and Guangdong Mesing in proportion to their shareholdings in the Joint Venture Company. Therefore, registered capital of RMB15.3 million will be payable in cash by CS Fund to the Joint Venture Company and the maximum obligation of provision of guarantee for future financing of the Joint Venture Company is RMB30 million.

The aforesaid capital contribution and the future funding of the Joint Venture Company were arrived at after arm's length negotiations among the parties to the Agreement and were determined with reference to, among other things, business development, future financing needs and prospects of the Joint Venture Company.

The Directors consider that the terms of the Joint Venture Agreement are fair and reasonable and in the interest of the Company and Shareholders as a whole.

By order of the Board
**Common Splendor International
Health Industry Group Limited**
Wong Yuet Ying
Company Secretary

Hong Kong, 22 July 2014

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen and Mr. Cheng Hau Yan as executive Directors; Mr. Lin Jiang as non-executive Director; and Mr. Mai Yang Guang, Mr. Yau Chi Ming and Mr. Huang Liang as independent non-executive Directors.

The website of the Company is <http://www.cs-ih.com>

**For identification only*